

Correlation between Serum Homocysteine and Vitiligo Area Scoring Index

Dina R. U. Hasibuan^{*}, Imam B. Putra, Nelva K. Jusuf

Dermatovenereology, Faculty of Medicine, University of Sumatera Utara, Medan, North Sumatera, Indonesia

Abstract

Citation: Hasibuan DRU, Putra IB, Jusuf NK. Correlation between Serum Homocysteine and Vitiligo Area Scoring Index. *Open Access Maced J Med Sci*. <https://doi.org/10.3889/oamjms.2017.066>

Keywords: Vitiligo; serum homocysteine; pathogenesis.

***Correspondence:** Dina R. U. Hasibuan, Dermatovenereology, Faculty of Medicine, University of Sumatera Utara, Medan, North Sumatera, Indonesia. E-mail: dina.afif.almahdaly@gmail.com

Received: 02-Mar-2017; **Revised:** 11-Apr-2017; **Accepted:** 18-Apr-2017; **Online first:** 11-Jun-2017

Copyright: © 2017 Dina R. U. Hasibuan, Imam B. Putra, Nelva K. Jusuf. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Funding: This research did not receive any financial support.

Competing Interests: The authors have declared that no competing interests exist.

BACKGROUND: Vitiligo is a chronic skin disorder. White macules caused by melanocyte destruction is a characteristic finding that cosmetically disturbing. Until recently, pathogenesis of vitiligo is still unclear. The role of homocysteine in vitiligo is mentioned in previous studies thus it is probable that it can be a biomarker to determine vitiligo severity.

AIM: To determine correlation between serum homocysteine and vitiligo area Scoring Index (VASI)

SUBJECT AND METHOD: This was a cross-sectional analytic study which involved 30 vitiligo patients that were diagnosed by clinical and Wood's lamp examinations then VASI score was determined and same numbers of control. We conducted blood sampling and measurement of serum homocysteine level to the patients.

RESULTS: There is no significant correlation between serum homocysteine and VASI score ($p = 0.133$, $r = 0.281$), family history ($p = 0.706$), and duration of vitiligo ($p = 0.993$, $r = 0.002$). There is no significant difference between serum homocysteine in vitiligo patients and controls ($p = 0.905$). There is a correlation between serum homocysteine with gender ($p = 0.001$) and age ($p = 0.036$; $r = 0.385$) in vitiligo patient.

CONCLUSION: There is no significant correlation between serum homocysteine and VASI score, family history, and duration of vitiligo. There is no significant difference between serum homocysteine in vitiligo patients and controls. There is a correlation between serum homocysteine with gender and age in vitiligo patient.

Introduction

Vitiligo is a skin depigmentation disorder with the characteristic as a white macule caused by melanocyte destruction. Aetiology of vitiligo is still unknown. But there are several hypotheses like genetic, autoimmune and biochemistry [1-3]. This hypothesis was thought to simultaneously work together and caused vitiligo. Genetic predisposition can trigger autoimmune process, and with the addition of oxidative stress, elevation can result in the destruction of melanocyte, therefore, inducing white macule in vitiligo subjects [4].

One compound thought to be involved in this hypothesis is homocysteine [5]. Homocysteine-mediated melanocyte destruction via production of interleukin-6 (IL-6), activating *nuclear factor-kappa B* (NF- κ B) and increased oxidative stress [6].

Subjects and Methods

This was a cross-sectional analytic study involving 30 vitiligo patients and 30 controls who were 18 years old or above and submitted to the outpatient dermatology and venereology clinic in Haji Adam Malik General hospital, Medan, North Sumatera, Indonesia. This study conducted from June until October 2016. Each subject signed informed consent were included in this study. Exclusion criteria were consumption of vitamin B₆, B₁₂, and folic acid within the last 6 months, breastfeeding, pregnancy, and vitiligo treatment during the last 6 months. Ethical clearance was given by Health Research Ethical Committee, Faculty of Medicine, University of Sumatera Utara.

All subjects with vitiligo were diagnosed by clinical and Wood's lamp examinations. VASI score was determined by calculating body part involved and depigmentation severity. VASI was calculated using a formula that includes contributions from all body

regions (possible range, 0–100). VASI = \sum Hand Units of all body sites \times Residual Depigmentation. One hand unit, which encompasses the palm plus the volar surface of all the digits, is approximately 1% of the total body surface area. It is used as a guide to estimate the baseline percentage of vitiligo involvement in each body region. The body was divided into separate regions: upper extremities (excluding hands), hands, trunk, lower extremities (excluding feet), feet and head and neck. The axillary region was included with the upper extremities while the buttocks and inguinal areas were included with the lower extremities.

The extent of residual depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. At 100% depigmentation; no pigment was present, at 90%; specks of pigment were present, at 75%; the depigmented area exceeded the pigmented area, at 50%; the depigmented and pigmented areas were equal, at 25%; the pigmented area exceeded the depigmented area, at 10%; only specks of depigmentation were present.

Fasting blood sample from subjects then processed into the serum. Homocysteine level was measured from serum by using ADVIA Centaur HCY[®].

The results were analysed with SPSS version 19. Quantitative data were analysed using mean and SD. The Student t-test was used to compare the means of different groups. Spearman test was used to determine relationships. P values less than 0.05 were considered significant.

Results

There is no significant correlation between serum homocysteine and VASI score ($p = 0.133$, $r = 0.281$), family history ($p = 0.706$), and duration of vitiligo ($p = 0.993$, $r = 0.002$).

Table 1: Serum homocysteine level in vitiligo subjects and controls

Subjects	Mean ($\mu\text{mol/L}$)	Serum homocysteine level Standard Deviation ($\mu\text{mol/L}$)	p
Vitiligo	10.66	2.89	0.905
Control	10.58	2.01	
Male	13.02	1.48	0.001
Female	9.81	2.81	
Positive family history	11.07	2.16	0.706
Negative family history	10.56	3.08	

There is a correlation between serum homocysteine with gender ($p = 0.001$) and age ($p = 0.036$; $r = 0.385$) in vitiligo patient. There is no significant difference between serum homocysteine in vitiligo patients and controls ($p = 0.905$).

Table 2: Correlation between the serum homocysteine with VASI score and other variables

	p	r
Serum homocysteine with VASI score	0.133	0.281
Serum homocysteine with age of vitiligo subjects	0.036	0.385
Serum homocysteine serum with duration of disease	0.993	0.002

Discussion

In this study we didn't find any significant correlation between serum homocysteine level and VASI score ($p > 0.05$; $r = 0.281$). This is in agreement with another study in Dr M. Djamil Padang, which conducted a study with 17 samples ($r = 0.061$; $p > 0.05$) [7].

A similar finding by Zaki et al. in Egypt also didn't find any significant relation between serum homocysteine level and VASI score ($p > 0.05$). Zaki et al. reveal this study used VASI score instead of rules of nine like in other studies. VASI score evaluates vitiligo lesion both quantitatively and qualitatively [8].

This result was in disagreement with El-Dawela and Abou-elf touch who conducted a study with 70 samples and found a correlation between VASI score and homocysteine serum ($r = 0.835$, $p = 0.001$) with mean VASI score was 9.5 ± 19.5 [9]. Similar findings found by Agarwal et al in India with 50 vitiligo subjects ($r = 0.567$; $p = 0.000$). In this study VASI score ≥ 30 significantly higher than VASI score < 30 ($p = 0.001$) [6]. Sabry et al. in an outpatient clinic in Benha University Hospital, Egypt with 35 subjects found serum homocysteine level and the extent of vitiligo ($p = 0.001$; $r = 0.559$). In this study vitiligo extent assessed using rules of nine [10].

Until now, it is still unclear about the underlying pathogenesis of vitiligo. Homocysteine was one compound thought to be involved in vitiligo. Homocysteine can induce oxidative damage, producing IL-6 and activating NF- κ B which results in melanocyte destruction. IL-6 can increase the expression of intercellular adhesion molecule-1 that will stimulate adhesion melanocyte to leucocyte, inducing activation of polyclonal B cell and increasing production of autoantibody [11]. Activation of NF- κ B by homocysteine then modulate expression of pro-apoptotic p53 in vitiligo lesion [12]. All of these could damage melanocyte [11, 12].

Other than that homocysteine also can produce oxidative stress, accumulate melanocytotoxic compound and inhibit natural detoxification which contributing in melanocyte destruction. Homocysteine can also affect tyrosinase in melanin synthesis at enzyme's active location. Free homocysteine also can react nonenzymatically with sulfhydryl and thiolation

can also occur. Both of which can affect the function of enzyme and protein [10, 13, 14].

In this study, there is no significant difference of serum homocysteine in vitiligo and control ($p = 0.905$). Factors affecting homocysteine are genetic, blood vitamin, sex, age, life style, drugs, hyperproliferating disease, renal failure, heart failure and diabetes mellitus [5, 15]. A similar finding was found by Zaki et al. who didn't find any difference between vitiligo subjects and control ($p = 0.191$) [8].

In disagreement, Singh et al at Sir Sunderhal Hospital, Varanasi, India with 200 vitiligo subjects and 75 controls found homocysteine level was significantly higher than control [16]. El-Dawela, Abou-elfetouh, Sabry and Agarwal found similar results [6, 9].

In conclusion, there is no significant correlation between serum homocysteine and VASI score, family history, and duration of vitiligo. There is no significant difference between serum homocysteine in vitiligo patients and controls. There is a correlation between serum homocysteine with gender and age in vitiligo patient. Further study needed to determine the pathogenesis of vitiligo and whether homocysteine had an influence on that.

References

1. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A comprehensive overview part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. *J Am Acad Dermatol*. 2011;65:473-91. <https://doi.org/10.1016/j.jaad.2010.11.061> PMID:21839315
2. Birlea SA, Spritz RA, Noris DA. Vitiligo. In: Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffel DJ, Wolff K, editors. *Fitzpatrick's dermatology in general medicine*. 8th ed. New York: The McGraw-Hill companies, 2012: p. 1308-24.
3. Yaghoobi R, Omidian M, Bagherani N. Vitiligo: A review of the published work. *Journal of Dermatology*. 2011;38:419-31. <https://doi.org/10.1111/j.1346-8138.2010.01139.x> PMID:21667529
4. Karadag AS, Tural E, Ertugrul DT, Akint KO, Bilgili SG. Serum holotranscobalamine, vitamin B12, folic acid and homocysteine levels in patients with vitiligo. *Clin Exp Dermatol*. 2011; 37: 62-4. <https://doi.org/10.1111/j.1365-2230.2011.04142.x> PMID:22182436
5. Bolander-Gouaille C. Homocysteine, the new marker of disease risk-an overview. *Business briefing: European pharmacotherapy*. 2005;2-8.
6. Agarwal S, Mendiratta V, Chander R, Jain A, Yadav P. Study of serum levels of Vitamin B, folic acid, and homocysteine in vitiligo. *Pigment Int*. 2015;2:76-80. <https://doi.org/10.4103/2349-5847.172777>
7. Elhuda. Hubungan kadar homosistei serum dengan skor vitiligo area scoring index (VASI) . Sp. DV [Tesis]. Padang: Universitas Andalas, 2016.
8. Zaki AM, Abdo HM, Ibrahim IM, Ibrahim AEKI. Serum homocysteine and vitiligo. *The gulf journal of dermatology and venereology*. 2014 ;21(2): 15-20.
9. El-Dawela RE, Abou-elfetouh S. Relationship between homocysteine, vitamin B12, folic acid levels and vitiligo. *J Appl Sci Res*. 2012; 8(11): 5528-35.
10. Sabry HH, Sabry JH, Hashim HM. Serum levels of homocysteine, vitamin B12, and folic acid in vitiligo. *Egypt J Dermatol Venerol*. 2014;34:65-9. <https://doi.org/10.4103/1110-6530.137315>
11. Becatti M, Prigano F, Fiorillo, Pescitelli L, Nassi P, Lotti T, Taddei N. The involvement of Smac/DIABLO, p53, NF- κ B, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: protective effects of curcumin and capsaicin. *Antioxidants & Redox Signaling*. 2010; 13(9):1309-21. <https://doi.org/10.1089/ars.2009.2779> PMID:20085492
12. Yu H, Chang K, Yu C, Li H, Wu M, Wu C, et al. Alterations in IL-6, IL-8, GM-CSF, TNF- α , and IFN γ release by peripheral mononuclear cells in patients with active vitiligo. *J invest Dermatol*. 1997;108: 527 -9. <https://doi.org/10.1111/1523-1747.ep12289743> PMID:9077486
13. Ghalamkarpour F, Jafarian Z, Einollahi H, Younespour S. Homocysteine: is it a biomarker for vitiligo? *Journal of pigmentary disorders*. 2015; 2(4): 1-4.
14. Silverberg JI, Silverberg NB. Serum homocysteine as a biomarker of vitiligo vulgaris severity: A pilot study. *J Am Acad Dermatol*. 2011. 64(2):445-7. <https://doi.org/10.1016/j.jaad.2010.08.025> PMID:21238838
15. Selhub J. Homocysteine metabolism. *Annu Rev Nutr*. 1999; 19:217-46. <https://doi.org/10.1146/annurev.nutr.19.1.217> PMID:10448523
16. Singh S, Singh U, Pandey SS. Serum folic acid, vitamin B12 and homocysteine levels in Indian vitiligo patients. *EDOJ*. 2012; 8(1):1-7.